4YVX
Crystal structure of AKR1C3 complexed with glimepiride
Summary for 4YVX
Entry DOI | 10.2210/pdb4yvx/pdb |
Related | 4YVP 4YVV |
Descriptor | Aldo-keto reductase family 1 member C3, 3-ethyl-4-methyl-N-[2-(4-{[(cis-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-car boxamide, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, ... (4 entities in total) |
Functional Keywords | akr1c3 inhibitor, oxidoreductase-oxidoreductase inhibitor complex, oxidoreductase/oxidoreductase inhibitor |
Biological source | Homo sapiens (Human) |
Cellular location | Cytoplasm: P42330 |
Total number of polymer chains | 2 |
Total formula weight | 76280.50 |
Authors | |
Primary citation | Zhao, Y.,Zheng, X.,Zhang, H.,Zhai, J.,Zhang, L.,Li, C.,Zeng, K.,Chen, Y.,Li, Q.,Hu, X. In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis Chem.Biol.Interact., 240:310-315, 2015 Cited by PubMed Abstract: Recent epidemiological studies show conflicting data for the first-line anti-diabetic sulphonylureas drugs in treating cancer progression in type II diabetes patients. How sulphonylureas promote or diminish tumor growth is not fully understood. Here, we report that seven sulphonylureas exhibit different in vitro inhibition towards AKR1Cs (AKR1C1, AKR1C2, AKR1C3), which are critical steroid hormone metabolism enzymes that are related to prostate cancer, breast cancer and endometrial diseases. Interactions of the sulphonylureas and AKR1Cs were analyzed by X-ray crystallography. PubMed: 26362498DOI: 10.1016/j.cbi.2015.09.006 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.3 Å) |
Structure validation
Download full validation report